Atlas Trials

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Clinical trial NCT05233358 · UNKNOWN

Trial details

NCT number
NCT05233358
Sponsor
The Central Hospital of Lishui City
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2022-02-01
Primary completion
2023-02-01
Enrollment
176

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.